Synapse - Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer Journal Article

Authors:	Carrasquillo, J. A.; O'Donoghue, J. A.; Pandit-Taskar, N.; Humm, J. L.; Rathkopf, D. E.; Slovin, S. F.; Williamson, M. J.; Lacuna, K.; Aksnes, A. K.; Larson, S. M.; Scher, H. I.; Morris, M. J.
Article Title:	Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
Abstract:	Purpose: 223Ra-Dichloride (223Ra) is a novel bone-seeking alpha-emitter that prolongs survival in patients with castration-resistant metastatic prostate cancer. We conducted a study to better profile the pharmacokinetics, pharmacodynamics, and biodistribution of this agent. Methods: Ten patients received either 50, 100, or 200 kBq of 223Ra per kilogram of body weight. Subsequently, six of these ten patients received a second dose of 50 kBq/kg. Pharmacokinetics and biodistribution were assessed by serial blood sampling, planar imaging, and whole-body counting. Pharmacodynamic assessment was based on measurements of prostate-specific antigen, bone alkaline phosphatase, and serum N-telopeptide. Safety was also assessed. Results: Pharmacokinetic studies showed rapid clearance of 223Ra from the vasculature, with a median of 14 % (range 9-34 %), 2 % (range 1.6-3.9 %), and 0.5 % (range 0.4-1.0 %) remaining in plasma at the end of infusion, after 4 h, and after 24 h, respectively. Biodistribution studies showed early passage into the small bowel and subsequent fecal excretion with a median of 52 % of administered 223Ra in the bowel at 24 h. Urinary excretion was relatively minor (median of 4 % of administered 223Ra). Bone retention was prolonged. No dose-limiting toxicity was observed. Pharmacodynamic effects were observed (alkaline phosphatase and serum N-telopeptides) in a significant fraction of patients. Conclusion: 223Ra cleared rapidly from plasma and rapidly transited into small bowel, with fecal excretion the major route of elimination. Administered activities up to 200 kBq/kg were associated with few side effects and appeared to induce a decline in serum indicators of bone turnover. © 2013 Springer-Verlag Berlin Heidelberg.
Keywords:	prostate cancer; bone metastases; radium; radionuclide therapy; alpharadin; 223ra
Journal Title:	European Journal of Nuclear Medicine and Molecular Imaging
Volume:	40
Issue:	9
ISSN:	1619-7070
Publisher:	Springer
Date Published:	2013-09-01
Start Page:	1384
End Page:	1393
Language:	English
DOI:	10.1007/s00259-013-2427-6
PROVIDER:	scopus
PUBMED:	23653243
PMCID:	PMC5468165
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84881630281&partnerID=40&md5=8f3d745c7b2e5754a8f8adf99450be15
Notes:	--- - "Export Date: 4 September 2013" - "CODEN: EJNMA" - "Source: Scopus"